Polymorphisms in the Human Matrix Metalloproteinase Genes MMP1, MMP3, and MMP9: Genetic Risk Factors of Primary Open Angle Glaucoma?

• Sponsor: Medical University of Vienna (Other)
• Overall Status: Completed
• CT.gov ID: NCT00312403
• Collaborator: (none)
• Enrollment: 400
• Location: 1
• Arms: 2
• Duration (Months): 49
• Patients Per Site Per Month: 8.2

Study Details

Study Description

Brief Summary

Matrix metalloproteinases (MMPs) fulfill diverse important molecular functions and play pivotal roles in development, tissue morphogenesis, repair, aging, and inflammatory processes. MMPs are also important disease modulating factors, such as cancer, cardiovascular disease, rheumatoid arthritis or macular degeneration. Functional genetic variants have been described to fine-tune MMP activities at the gene transcriptional level and have been associated with increased genetic risk of e.g. arteriosclerosis or cancer. MMPs are also assumed to play a major role in the remodeling of the extracellular matrix (ECM) in the optic nerve head during glaucomatous optic neuropathy. MMP-1, MMP-3 and MMP-9 have been shown to be up-regulated in a variety of animal models of glaucoma. Here, we study three promoter SNPs within the genes encoding three members of the MMP family. By assessing the prevalence of genetic variants associated with either increased/decreased enzyme activity, we will (i) estimate their contribution to the genetic risk of developing primary open angle glaucoma (POAG) and (ii) investigate the potential role of MMPs in the functional pathology of POAG.

Condition or Disease	Intervention/Treatment	Phase
Glaucoma	Procedure: Blood Sample	N/A

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 400 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Diagnostic
• Official Title: Polymorphisms in the Human Matrix Metalloproteinase Genes MMP1, MMP3, and MMP9: Genetic Risk Factors of Primary Open Angle Glaucoma?
• Study Start Date: Nov 1, 2005
• Actual Primary Completion Date: Nov 1, 2009
• Actual Study Completion Date: Dec 1, 2009

Arms and Interventions

Arm	Intervention/Treatment
Other: 1 Patients with primary open angle glaucoma	Procedure: Blood Sample; A single venous blood sample will be taken (10 ml).
Other: 2 Age- and sex-matched control subjects	Procedure: Blood Sample; A single venous blood sample will be taken (10 ml).

Outcome Measures

Primary Outcome Measures

1. Genotyping results and putatively associated odds with occurence of primary open angle glaucoma. [15 minutes]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 40 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Men and women older than 39 years

• Primary open angle glaucoma as evidenced from characteristic visual field loss and optic disc cupping (POAG group)

• Healthy subjects matched by age, sex and ethnicity to the POAG patients group (control group)

Exclusion Criteria:

• Exfoliation glaucoma, pigmentary glaucoma

• History of acute angle closure

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Department of Clinical Pharmacology	Vienna		Austria	1090

Sponsors and Collaborators

• Medical University of Vienna

Investigators

• Principal Investigator: Gabriele Fuchsjaeger-Mayrl, M.D., Department of Clinical Pharmacology, Medical University of Vienna

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• ClinicalTrials.gov Identifier: NCT00312403
• Other Study ID Numbers: OPHT-300505
• First Posted: Apr 10, 2006
• Last Update Posted: Jan 15, 2010
• Last Verified: Jan 1, 2010

• Keywords provided by , ,: Glaucoma; Gene Polymorphism; Metalloproteinase
• Additional relevant MeSH terms: Glaucoma; Glaucoma, Open-Angle

Study Results

No Results Posted as of Jan 15, 2010